These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15517125)

  • 1. [Are "biologics" in the treatment of rheumatoid arthritis really cost effective?].
    Müller-Ladner U
    Internist (Berl); 2004 Dec; 45(12):1402-6. PubMed ID: 15517125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.
    Joensuu JT; Huoponen S; Aaltonen KJ; Konttinen YT; Nordström D; Blom M
    PLoS One; 2015; 10(3):e0119683. PubMed ID: 25781999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
    Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
    Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.
    Gissel C; Götz G; Repp H
    Z Rheumatol; 2016 Dec; 75(10):1006-1015. PubMed ID: 27080399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
    Rheumatol Int; 2016 Dec; 36(12):1627-1632. PubMed ID: 27778067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics-based therapy for the treatment of rheumatoid arthritis.
    Scott DL
    Clin Pharmacol Ther; 2012 Jan; 91(1):30-43. PubMed ID: 22166850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
    Linde L; Sørensen J; Østergaard M; Hetland ML
    J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
    Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
    J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making smart investment decisions in clinical research.
    Bansback N; Keystone E; O'Dell J; Phibbs CS; Hannagan K; Brophy M; Anis A
    Trials; 2015 Dec; 16():590. PubMed ID: 26712327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.